EGFR and neoplasm: Outcomes were substantially better in the EGFR T790M+ population compared to T790M− tumor patients with an ORR of 61% [95% CI, 52–70%] vs. 21% [95% CI, 12–34%], a DCR of 95% [95% CI, 90–98%] vs. 61% [95% CI, 47–73%] and median PFS of 9.6 months [95% CI, 8.3–not reached] vs. 2.8 months [95% CI, 2.1 to 4.3], respectively (36).